DISCUSSION

A unique point of this case is the development of anaphylactoid reactions several hours after exposure to the hair dyes, which gradually worsened over the following several days. PPD and its derivatives may cause delayed-type- as well as immediate-type-like reactions, although the related mechanism is not clearly understood. The current case might likely be due to combined immediate and delayed hypersensitivity to hair dye,\(^2,3\) though the immediate hypersensitivity observed in this patient was atypical.

The positive skin reactions to PPD and PTD-containing HD-A suggests that the patient might be allergic to both PPD and PTD. Unfortunately, as PTD was unavailable to us, we could not test it. The negative result of PPD-containing HD-B in the open test might be due to a lower PPD concentration in HD-B, as this was a “light hair colour” shade.

Unexpectedly, the patient experienced systemic anaphylactoid reactions 16 hours after closed patch testing. As she had been hospitalized during the skin tests, we could respond promptly. Therefore, caution must be exercised, especially for patients with a history of anaphylactoid symptoms, to avoid possible systemic reactions during skin tests for hair dye.

CONFLICTS OF INTEREST

The authors declare no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

Junko Sowa-Osako: Conceptualization; data curation; investigation; writing-original draft; writing-review and editing. Kazuyoshi Fukai: Conceptualization; data curation; writing-original draft; writing-review and editing. Daisuke Tsuruta: Conceptualization; supervision; writing-original draft; writing-review and editing.

ORCID

Junko Sowa-Osako https://orcid.org/0000-0002-8192-5077
Kazuyoshi Fukai https://orcid.org/0000-0002-9807-1397
Daisuke Tsuruta https://orcid.org/0000-0001-6283-0251

REFERENCES

1. Pasche-Koo F, French L, Piletta-Zanin P-A, Hauser C. Contact urticaria and shock to hair dye. Allergy. 1998;53(9):904-905.
2. Iwata JI, Inomata N, Sato M, Miyakawa M, Kawaguchi T, Aihara M. Contact dermatitis with concomitant contact urticaria syndrome due to multiple ingredients of oxidative hair dye. Allergol Int. 2019;68(1):114-116.
3. Nosbaum A, Dupin C, Nicolas JF, Bérard F. Severe immediate hypersensitivity and allergic contact dermatitis caused by hair dyes. Contact Dermatitis. 2012;67(1):52-53.

How to cite this article: Sowa-Osako J, Fukai K, Tsuruta D. Anaphylactoid reaction during patch testing for hair dye: A risk of skin testing. Contact Dermatitis. 2021;84:123–124. https://doi.org/10.1111/cod.13680

Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab

Laura Loman\(^1\) | Gilles F.H. Diercks\(^2\) | Marie L.A. Schuttelaar\(^1\)

\(^1\)Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
\(^2\)Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Correspondence
Marie L.A. Schuttelaar, Department of Dermatology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Email: m.l.a.schuttelaar@umcg.nl

KEYWORDS: dupilumab, hand dermatitis, hand eczema, hyperkeratotic hand eczema, treatment
Dupilumab, a monoclonal antibody inhibiting interleukin (IL)-4 and IL-13 signaling, is currently approved for the treatment of atopic dermatitis (AD). Effective treatment of hand eczema with dupilumab has been reported previously in case series, two small retrospective cohorts, and one prospective observational study including atopic, irritant and vesicular hand eczema subgroups. However, the effect of dupilumab on isolated hyperkeratotic hand eczema (HHE) has not yet been described.

METHODS

Three patients with moderate to severe HHE were treated with dupilumab 600 mg subcutaneously on day 1, followed by 300 mg subcutaneously every 14 days. A minimum washout of topical treatment of 2 weeks was applied. All patients underwent patch testing and no relevant contact allergies were detected. Concomitant fungal infections were ruled out and the diagnosis HHE was confirmed by histopathology.

Age, sex, disease duration, occupation, smoking status, treatment history, exposure to irritants, atopic comorbidities, and specific immunoglobulin E (IgE) inhalant allergens were assessed at baseline. Therapeutic response was evaluated every 4 weeks up to 16 weeks of treatment by the hand eczema severity index (HECSI), the photographic guide, clinical photographs, Quality of Life in Hand Eczema Questionnaire (QOLHEQ), and the weekly average of the number rating scale (NRS) for pain and pruritus (0–10, with 10 being the worst pruritus/pain).

RESULTS

Two males and one female, of respectively 65, 47 and 65 years of age, were treated (Appendix S1). All of them were previously treated with ultra-potent topical corticosteroids and at least two different systemic therapies, alitretinoin, among others. Case 1 had an inadequate response to alitretinoin, Cases 2 and 3 were intolerant to alitretinoin. None of the patients had a history of AD. Case 1 was a current smoker with 88 pack-years and experienced occupational exposure to irritants as a bricklayer by friction and wearing gloves during part of the day. All lesional skin biopsies presented identical histopathologic features (Appendix S2).

Two patients (case 2 and 3) had already major improvement after 4 weeks and symptoms cleared completely after 16 weeks of treatment. Case 1 noticed minimal clinical improvement, however, there was an improvement in itch and quality of life (Figure 1).

DISCUSSION

The pathogenesis of HHE remains largely unclear. A previous study on the gene and protein expression of hand eczema, including 15 patients with chronic hyperkeratotic-fissured hand eczema showed, among others, increased proliferative cell activity indicated by Ki-67, and a decreased expression of the terminal differentiation marker loricrin in palmar lesional skin biopsies, which was normalised following alitretinoin treatment. Another study showed an upregulation in keratinocyte host defence mechanism proteins (S100A7/S100A8/S100A9) in six patients with chronic hand eczema, including different subtypes, compared to healthy control skin. A study on protein expression in seven patients with HHE, showed also increased proliferative cell activity indicated by Ki-67 and a strong upregulation of keratin (K)16 with, in addition, a decreased expression of loricrin in lesional palmar skin compared to perilesional skin and healthy control skin. In patients with AD treated with dupilumab a significantly reduced gene expression of K16 and MKi67, a reduced expression of S100As genes, and an increase in loricrin expression is seen after treatment. Therefore, the good effect of dupilumab on HHE could be explained by the similarities in the epidermal pathology in patients with AD and HHE, including epidermal hyperproliferation and an impaired epidermal barrier.

Lack of clinical improvement in Case 1 might be explained by his occupational activities as a bricklayer, whereby hand eczema is also caused by exposure to irritants and friction. To date, no consensus has been reached on the classification system of hand eczema. It depends on the classification system if HHE is classified as an endogenous subtype without identifiable cause or if it could have contributing identifiable causes such as exposure to irritants. However, only one case report published the successful dupilumab treatment of occupational irritant hand dermatitis. However, it is possible that the role of different cytokines (including IL-4) is affected by several other factors, such as the identity of the topical irritant or to what extent the irritant factor contribute to the etiology. Another contributing factor to the lack of clinical effect could be that the patient was smoking.

Previous literature has showed successful results of dupilumab on hand eczema in patients treated for AD and in individuals with isolated vesicular hand eczema. In view of the good effect of dupilumab on HHE as well, it might be hypothesized that, despite the differences in phenotype, there are similarities in endotype and underlying pathogenesis with an IL-4/IL-13 driven inflammation between different subtypes of hand eczema. Therefore, dupilumab could be considered as an effective treatment of severe hand eczema, regardless of subtype. This should be investigated in future studies.

CONFLICTS OF INTEREST

Dr Schuttelaar is a member of advisory boards and received consultancy fees and fees for arranging education from Sanofi-Genzyme and Regeneron. The other authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Laura Loman: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; visualization; writing—original draft; writing—review and editing. Gilles Diercks: Visualization; writing—review and editing. Marie Schuttelaar: Conceptualization;
formal analysis; investigation; methodology; supervision; writing-
original draft; writing-review and editing.

ORCID
Laura Loman https://orcid.org/0000-0003-2731-9284
Gilles F.H. Diercks https://orcid.org/0000-0001-8053-216X
Marie L.A. Schuttelaar https://orcid.org/0000-0002-0766-4382

REFERENCES
1. Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019;46(8):680-685.
2. Waldman RA, DeWane ME, Sloan B, Grant-Kels JM, Lu J. Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients. J Am Acad Dermatol. 2020;82(5):1251-1252.
3. Lee N, Chipalkatti N, Zancanaro P, Kachuk C, Dumont N, Rosmarin D. A retrospective review of Dupilumab for hand dermatitis. Dermatology. 2019;235(3):187-188.
4. Halling AS, Zachariae C, Thyssen JP. Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab. Contact Dermatitis. 2020;83(1):37-38.
5. Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302-307.
6. Coenraads PJ, Van Der Walle H, Thstrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol. 2005;152(2):296-301.
7. Oosterhaven JAF, Ofenloch RF, Schuttelaar MLA. Validation of the Dutch quality of life in hand eczema questionnaire (QOLHEQ). Br J Dermatol. 2019;183(1):86-95.
8. Kumari V, Timm K, Kuhl AA, Heine G, Worm M. Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema. Br J Dermatol. 2016;175(6):1243-1250.
9. Molin S, Merl J, Dietrich KA, et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015;172(4):994-1001.
10. Politiek K, Loman L, Pas HH, et al. Hyperkeratotic hand eczema: eczema or not? Contact Dermatitis. 2020;83(2):196-205.

FIGURE 1: Clinical improvement of the three cases after 16 weeks of dupilumab treatment. (1A, 2A,3A) case 1, 2 and 3 at baseline, (1B, 2B, 3B) case 1, 2, 3 after 16 weeks of treatment.
Allergic contact dermatitis caused by a traditional Chinese medicine treatment—moxibustion

Zhen Xie | Yan Zhang | Ya-Ting Yang | Yang Su | Hao Zhang

Moxibustion is a traditional Chinese medicine (TCM) therapy using moxa wool made from dried Artemisia argyi, which is widely used in the treatment and prevention of various diseases worldwide by applying burning moxa to stimulate the human body surface. The common types of moxibustion include moxa cone (direct moxibustion or indirect moxibustion), moxa roll, and moxibustion with warmed needles. Doctors, especially traditional Chinese practitioners, believe that moxibustion has an active regulating functions of the body to improve and rectify the disturbance and dysfunction of certain organs in the body.

CASE REPORT

A 28-year-old man was referred to us for 12 itchy and eczematous patches with well-defined borders on the anterior aspect of the chest, abdomen, and back, corresponding to the contact areas of smokeless packages with ignited moxa in metal boxes for indirect moxibustion (Figure 1). Four days before, the patient purchased a moxibustion device from an online store, to achieve the purpose of strengthening the body's resistance and eliminating pathogens from the body. The method is to insert the moxa cone (burning at one end) into the box and close it, and then put the moxibustion box into the smokeless bag and fix the moxibustion area with an elastic band (Figure 2). According to this procedure, moxibustion was performed on his chest, abdomen, and back in turn, each for 20 minutes and without discomfort. A day later, dermatitis developed and worsened gradually at the contact areas of the smokeless bag containing the ignited moxa box, accompanied by obvious itching and slight pain. He has no history of allergic diseases such as eczema. Hence, we suspected allergic contact dermatitis (ACD) caused by the moxibustion. Dermatitis resolved after oral prednisone (30 mg/d for 4 days) and topical hydrocortisone butyrate cream 0.1% (twice daily for 1 week). After 2 months of follow-up, no recurrence was observed (Figure 2).

Patch tests with the Chinese baseline series (Chemotechnique Diagnostics, Vellinge, Sweden) showed positive reactions to...